Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:
“Now that adjuvant pembro plus Belzutifan is approved by FDA – How will you decide who needs 1 drug versus 2 drugs in adjuvant RCC?
pT3 NO clear cell RCC, Fit patients.
What will you u give in adjuvant?
Do vote below and opine.”
Other articles featuring Dr. Akhade on OncoDaily.